Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

FDA warns consumers not to use Intestinomicina for treatment of infectious diarrhea

The U.S. Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections.

19 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Researchers to probe causes, treatments of toxic reactions in blood plasma

In the largest undertaking of its kind, scientists at four leading U.S. research institutions are embarking upon a five-year National Institutes of Health (NIH)-funded study to make blood transfusions safer and more effective by uncovering the exact causes of hemoglobin toxicity.

18 Sep 2012

Parents of sickle cell babies undercounseled

Parents of newborns with the sickle cell anemia trait are significantly less likely to receive genetic counseling than those of babies who are cystic fibrosis carriers, say researchers.

17 Sep 2012

ASN's top five recommendations to avoid wasteful and harmful medical interventions

Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.

14 Sep 2012

IPS examines controversy over WHO-approved drug to prevent hemorrhage after labor

Inter Press Service examines the reaction to calls for the WHO "to reverse its listing in April 2011 of misoprostol among essential medicines that 'satisfy the health care needs of the majority of the population' and are 'available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford'" as a result of a study published in the August issue of the Journal of the Royal Society of Medicine.

13 Sep 2012

Combination chemotherapy confirmed viable for penile cancer

A combination of cisplatin and 5-fluorouracil is an effective and well-tolerated regimen for patients with squamous cell carcinoma of the penis, show study findings.

12 Sep 2012

Parents of infants with cystic fibrosis carriers more likely to receive genetic counseling

Parents of newborns with the sickle cell anemia trait were less likely to receive genetic counseling than parents whose babies are cystic fibrosis carriers, a new study from the University of Michigan shows.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Many pediatric respiratory hospitalizations unnecessary

Study findings suggest that a large number of pediatric hospitalizations, particularly those of a respiratory nature, could be prevented.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Distribution infrastructure, effective education important for success of micronutrient powders to treat childhood anemia

In this post in the New York Times' "Opinionator" blog, journalist Sam Loewenberg examines the administration of micronutrient powders as a treatment option for anemia, "one of the most pervasive problems affecting the world's children, and one that goes largely unaddressed."

7 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

Regular Fanconi anemia cells aren't sensitive to resveratrol

Fanconi anemia is a recessive genetic disorder affecting 1 in 350,000 babies, which leaves cells unable to repair damaged DNA. This lack of repair puts Fanconi anemia patients at high risk for developing a variety of cancers, especially leukemias and head and neck cancer.

5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Evidence lacking for use of misoprostol in PPH prevention

There is insufficient evidence for the effectiveness of misoprostol in preventing postpartum hemorrhage, suggest findings from a review of available research published in the Journal of the Royal Society of Medicine.

29 Aug 2012

Cyclin D3 protein regulates size and quantity of RBCs

The adult human circulatory system contains between 20 and 30 trillion red blood cells (RBCs), the precise size and number of which can vary from person to person. Some people may have fewer, but larger RBCs, while others may have a larger number of smaller RBCs. Although these differences in size and number may seem inconsequential, they raise an important question: Just what controls these characteristics of RBCs?

29 Aug 2012

Anemia News and Research

Further Reading

FDA warns consumers not to use Intestinomicina for treatment of infectious diarrhea

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Researchers to probe causes, treatments of toxic reactions in blood plasma

Parents of sickle cell babies undercounseled

ASN's top five recommendations to avoid wasteful and harmful medical interventions

IPS examines controversy over WHO-approved drug to prevent hemorrhage after labor

Combination chemotherapy confirmed viable for penile cancer

Parents of infants with cystic fibrosis carriers more likely to receive genetic counseling

Scripps scientists discover new antibody-discovery technique

Many pediatric respiratory hospitalizations unnecessary

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Distribution infrastructure, effective education important for success of micronutrient powders to treat childhood anemia

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Regular Fanconi anemia cells aren't sensitive to resveratrol

FDA approves Bosulif to treat chronic myelogenous leukemia

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Evidence lacking for use of misoprostol in PPH prevention

Cyclin D3 protein regulates size and quantity of RBCs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News